5-Amino-1MQ
5-Amino-1-Methylquinolinium
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that regulates cellular energy metabolism and is upregulated in white adipose tissue of obese individuals. By blocking NNMT, it increases intracellular NAD+ and SAM (S-adenosyl methionine) concentrations, shifting fat cells from storage toward energy expenditure. It is primarily researched as an oral metabolic modulator for obesity, metabolic syndrome, and cellular energy optimization.
Mechanism of Action
Small molecule inhibitor of NNMT. Increases cellular NAD+ and SAM levels, activating SIRT1-dependent energy expenditure pathways.
Research Protocols
For research purposes only. Not medical advice.
Research protocols use 50-150mg orally once daily. Often taken with food.
Research Notes
Clinical Research Status
5-Amino-1MQ is in preclinical development with published in vitro and animal model data but has not yet entered formal human clinical trials. Research is primarily based on studies from the University of Texas Health Science Center demonstrating its effects on adipocyte differentiation and metabolic pathways. The compound is available through research chemical suppliers and compounding pharmacies, though it lacks regulatory approval for any therapeutic indication.
Key Published Findings
Studies in diet-induced obesity mouse models showed that 5-Amino-1MQ treatment reduced body weight by approximately 7% over 11 days without affecting food intake or causing lean mass loss. In vitro research demonstrated that NNMT inhibition with 5-Amino-1MQ reduced lipid accumulation in differentiating adipocytes and increased intracellular NAD+ levels by 2-fold. The compound has been shown to shrink existing fat cells, prevent new fat cell maturation, and increase the activity of sirtuin-dependent metabolic pathways through NAD+ elevation.
Safety Profile
Preclinical toxicity data suggests 5-Amino-1MQ is well-tolerated in animal models at effective doses without significant organ toxicity or behavioral changes. As a relatively new research compound without human trial data, the long-term safety profile in humans remains uncharacterized. Users in the research community have self-reported generally mild side effects at doses of 50-150mg daily, though systematic adverse event data is absent.
Drug Interactions & Contraindications
Theoretical interactions exist with other compounds that affect methyl donor metabolism, including SAM-e supplements and medications metabolized by methyltransferase enzymes. Given its mechanism of increasing intracellular NAD+, concurrent use with NAD+ precursors (NMN, NR) may produce additive effects that are not yet characterized for safety. Individuals with hormone-sensitive conditions should exercise caution, as NNMT plays roles in estrogen and catecholamine metabolism.
Comparison to Related Compounds
Unlike traditional fat loss compounds that work through appetite suppression or thermogenesis (DNP, clenbuterol), 5-Amino-1MQ targets the metabolic programming of fat cells themselves through epigenetic regulation. Other NNMT inhibitors exist in research (methylquinolinium analogs), but 5-Amino-1MQ is the most characterized and commercially available for research purposes. Its mechanism of simultaneously increasing NAD+ and SAM makes it mechanistically distinct from direct NAD+ precursors like NMN, which do not address NNMT-mediated metabolic dysregulation.
Community Observations
Users typically report subtle but measurable changes in body composition over 4-8 weeks at oral doses of 50-150mg daily, with fat loss concentrated in visceral and stubborn subcutaneous depots. The compound is frequently stacked with other metabolic agents and exercise programs, making isolated effects difficult to assess in anecdotal reports. The research community notes that 5-Amino-1MQ appears to work best as a recomposition agent rather than a dramatic weight loss compound, and effects seem more pronounced in individuals with higher baseline body fat percentages.
Half-Life
~2-3 hours (oral)
Reconstitution
N/A (oral capsule form)
Storage
Lyophilized
Room temperature. Protect from moisture and light.
Reconstituted
N/A (oral form)
US Legal Status
Also Known As
PeptideVault provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.
Read full disclaimer